Intra-therapeutic dosimetry of [¹⁷⁷Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.

ABSTRACT:

Introduction

While [¹⁷⁷Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit from it. However, there are toxicity concerns related to the sink effect in low-volume disease. This prospective study aims to determine the kinetics of [¹⁷⁷Lu]Lu-PSMA in mHSPC patients, analyzing the doses to organs at risk (salivary glands, kidneys, liver, and bone marrow) and tumor lesions < 1 cm diameter.

Methods

Ten mHSPC patients underwent two cycles of [¹⁷⁷Lu]Lu-PSMA therapy. Three-bed position SPECT/CT was performed at 5 time points after each therapy. Organ dosimetry and lesion dosimetry wer

SUBMITTER: Peters SMB 

PROVIDER: S-EPMC8803803 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature